FBC
IOVA icon

Fairfield, Bush & Co’s Iovance Biotherapeutics IOVA Stock Holding History

Fairfield, Bush & Co’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,575
Closed -$137K – 116
2024
Q3 		$137K Sell
14,575
-6,650
-31% -$63K 0.08% 110
2024
Q2 		$170K Sell
21,225
-225
-1% -$2.41K 0.1% 110
2024
Q1 		$318K Buy
21,450
+21,330
+17,775% +$248K 0.19% 92
2023
Q4 		$976 Buy
+120
New +$628 ﹤0.01% 437

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Fairfield, Bush & Co's IOVA Position: Q4 2024 in Review

Fairfield, Bush & Co sold out of Iovance Biotherapeutics (IOVA) in Q4 2024, closing a stake of 14,575 shares — an estimated $137K sold.

Fairfield, Bush & Co first reported a position in IOVA in Q4 2023 and held it in 4 quarters. The position peaked at $318K in Q1 2024. 301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

  • Fairfield, Bush & Co reported no remaining Iovance Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Fairfield, Bush & Co sold 14,575 Iovance Biotherapeutics shares in Q4 2024, an estimated $137K.
  • Fairfield, Bush & Co first reported a position in Iovance Biotherapeutics in Q4 2023 and held it in 4 quarters.
  • Fairfield, Bush & Co's Iovance Biotherapeutics position peaked at $318K in Q1 2024.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on Fairfield, Bush & Co's 13F filing for Q4 2024, filed 13 Feb 2025.